The investigated chr9:g.21971058C>A (hg38) founder mutation is the most frequently observed missense CDKN2A variant in familial melanoma cancers [28,29,30] with hints that the specific mutation might confer a higher risk of developing pancreatic cancer than other pathogenic CDKN2A variants [31]. The gene discussed is CDKN2A; the disease is pancreatic neoplasm.